Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CNS Pharmaceuticals Inc. (CNSP) Message Board

AI May Help Improve Brain Cancer Diagnosis Trad

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 367
(Total Views: 251)
Posted On: 06/29/2022 5:15:51 PM
Avatar
Posted By: NetworkNewsWire
AI May Help Improve Brain Cancer Diagnosis

Traditionally, brain tumors are diagnosed by computer topography scans (CT), magnetic resonance imaging (MRI) or a neurologic exam. However, researchers from the Karl Landsteiner University for Health Sciences (KL Krems) have now discovered a more precise and accurate way of diagnosing brain cancer by using artificial intelligence (AI) combined with physiological imaging.

The researchers used several multiclass machine learning techniques to study data sourced from MRIs and classified different brain tumors. They then compared the results produced through machine learning with classifications that were made by human specialists.

Although the experts were better at specificity and sensitivity, the researchers discovered that the AI was superior in terms of precision, accuracy and spotting misclassification.

This shows that machine learning can be used to improve brain cancer diagnosis. Although MRIs can be used to easily spot a brain tumor, making a classification with MRI data only can be difficult, which in turn makes choosing the optimal treatment option more challenging. The team from KL Krems sought to fix this issue by finding a more accurate way of making brain cancer diagnoses and classifications.

The researchers, led by Professor Andreas Stadlbauer, leveraged both physiological and advanced MRI data and used both datasets to gain a deeper understanding of the metabolism and structures of a brain tumor as well as find better ways to classify tumors. However, this would involve assessing an inordinate amount of data, hence the use of artificial intelligence and machine learning.

Stadlbauer explained that the study was instrumental in proving that machine learning can indeed be used to analyze MRI data and make more accurate brain tumor classifications.

First, the research team had to train nine multiclass machine learning algorithms using MRI data sourced from 167 patients who had one of the five most prevalent types of brain tumors. They then used histology, which is the study of the anatomy, structure, and role of animal and plant tissues, to teach the AIs precise classification.

Stadlbauer noted that his study also used data sourced from physiological MRIs, something that previous studies had not done. This included details on oxygen supply to tumors, how the tumors form new vessels and vascular structures of tumors.

After comparing classifications made by the AI with those made by human professionals, the research team found that the AI’s classifications were more accurate and precise.

Still, the team cautions against using AIs as a substitute for qualified personnel. Rather, machine learning could be used as a tool to supplement brain cancer diagnosis and find the most optimal treatments.

The researchers published their findings in the “Cancers” journal.

As some teams focus on improving brain cancer diagnosis, others at companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are looking to find new treatments that will improve patient outcomes. The convergence of these different efforts bodes well for the future of cancer care across the globe.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer



(0)
(0)




CNS Pharmaceuticals Inc. (CNSP) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us